Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.86 CHF | -0.44% | -8.53% | +96.56% |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.73M 1.65B | Sales 2023 | 33.56M 36.82M 3.07B | Capitalization | 128M 141M 11.75B |
---|---|---|---|---|---|
Net income 2022 | -14M -15.36M -1.28B | Net income 2023 | -13M -14.26M -1.19B | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.23M 2.02B | Net cash position 2023 | 12M 13.16M 1.1B | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
1 day | -0.44% | ||
1 week | -8.53% | ||
Current month | +13.20% | ||
1 month | +13.20% | ||
3 months | +51.10% | ||
6 months | +166.93% | ||
Current year | +96.56% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14/18/14 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 6.86 | -0.44% | 115,481 |
25/24/25 | 6.89 | +2.38% | 201,239 |
24/24/24 | 6.73 | -5.34% | 430,265 |
23/24/23 | 7.11 | -12.44% | 601,803 |
22/24/22 | 8.12 | +8.27% | 278,390 |
Delayed Quote Swiss Exchange, April 26, 2024 at 09:01 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+96.56% | 276M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KURN Stock